Recent Advances in Cancer Immunotherapy and Tumor Profiling Technologies

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

Cancer immunotherapy and cancer profiling are key areas of growth across the healthcare community. These vital areas will define the future of how cancer is screened, diagnosed, managed, and monitored. With technology areas such as exosome technology being implemented in profiling tumors, a paradigm shift can be brought about in how cancer is detected. Early detection of cancer will enable it to be controlled and managed in a better manner. New strides have been made in the development of immunological therapeutics, thereby increasing the treatment possibilities for patients suffering with certain types of hard to treat cancers. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D

Table of Contents

Recent Advances in Cancer Immunotherapy and Tumor Profiling TechnologiesInnovations in Cancer Immunotherapy and Tumor Profiling Technologies Monoclonal Antibody Therapy for Urothelial CarcinomaLeveraging Exosome Biology for Tumor ProfilingExosome Biomarkers for Chronic Traumatic EncephalopathyEnhancing Exosome Isolation for Research ApplicationsClinical Trial Analysis and Industry InteractionsClinical Trial AnalysisIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.